Article info
PDFClinical and epidemiological research
Extended report
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial
- Correspondence to Dr Renee S Martin, Anthera Pharmaceuticals, Inc, Hayward, California 94545, USA; rmartin{at}anthera.com
Citation
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial
Publication history
- Received January 16, 2018
- Revised March 1, 2018
- Accepted March 2, 2018
- First published March 21, 2018.
Online issue publication
May 10, 2018
Article Versions
- Previous version (21 March 2018).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.